Tilos Therapeutics was founded based on research from Drs. Howard Weiner and Galina Gabriely at the Brigham and Women’s Hospital. Dr. Weiner has been working for many years to understand the control factors that are altered in patients with serious autoimmune disease. That research led his lab to a focus on LAP (latency-associated peptide of TGF beta). The Weiner lab developed antibodies specific for LAP and Dr. Gabriely demonstrated that these antibodies can control tumor growth in a number of established animal models. The anti-LAP antibodies appear to be effective because LAP sits at the intersection of two important immune control points. LAP is expressed on regulatory T cells (Tregs) that govern the strength and direction of the immune system, and LAP functions to control the activity of a powerful cytokine, TGF beta, that governs inflammation, angiogenesis, metastasis, fibrosis, and more. Their work was published in 2017 in the leading journal Science Immunology (Gabriely et al. Targeting latency-associated peptide promotes antitumor immunity. Sci. Immunol. 2:eeaj1738 (2017)). Tilos is expanding on Drs. Weiner and Gabriely’s research to bring these antibodies into clinical development for cancer. The company also believes the antibodies have potential in the treatment of fibrosis and related disorders.